About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, July 14th, 2015

The QualityStocks
Daily Stock List


Tristar Wellness Solutions, Inc. (TWSI)

PennyStocks24, TopPennyStockMovers, Otcstockexchange, WhisperFromWallStreet, Center Stage Stocks, Pennystocktweeters.com, Pumps and Dumps, and MajorPennyStocks reported on Tristar Wellness Solutions, Inc. (TWSI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tristar Wellness Solutions, Inc. is a consumer health and wellness company listed on the OTCQB. It targets opportunities in the advanced wound care marketplace. The Company formerly went by the name BioPack Environmental Solutions, Inc. It changed its corporate name to TriStar Wellness Solutions, Inc. in January 2013. The Company has been built upon the Wound Care, Women’s Health and Therapeutic Skin Care product platforms.

Tristar Wellness Solutions has concentrated business development efforts on the Wound Care and Women’s Health platforms through a combination of strategic acquisitions and licensed technologies. Concerning acquisitions, it purchased HemCon® Medical Technologies, Inc. (founded in 2001) in May of 2013. This purchase provided access to greater than 70 U.S. and international patents defining the core wound care technology in bleeding control.

HemCon Medical Technologies, based in Portland, Oregon, develops, manufactures, and markets innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. The design of HemCon products are for use by military and civilian first responders and also medical professionals in hospital and clinical settings where control of bleeding are of critical importance. HemCon has subsidiaries in Ireland and the Czech Republic.

In March 2013, Tristar obtained an exclusive global license (Argentum® / Silverlon®) to market adapted professional products for the direct-to-consumer (DTC) wound care market. In addition, it signed an exclusive license agreement in June of 2012 (Beautè de Maman®). This led to the Asset Purchase Agreement concluded in February of 2013. This is a DTC natural products company. It was developed by a renowned obstetrician creating health and beauty products for pregnant and nursing women. Furthermore, Tristar, in February 2013, acquired “Soft and Smooth”. This is a novel feminine protection under development.

This past May, TriStar Wellness Solutions announced that its wholly-owned independent subsidiary HemCon Medical Technologies was awarded funding from the National Institutes of Health (NIH) to develop a novel chitosan endoluminal hemostatic dressing that can be delivered by a catheter to control and prevent prostatic bleeding during prostatic surgery such as transurethral resection of the prostate (TURP). Oregon Health & Science University (OHSU) will work with HemCon Medical Technologies as a subcontractor on development of the dressing.

Tristar Wellness Solutions, Inc. (TWSI), closed Tuesday's trading session at $0.15, down 40.00%, on 5,000 volume with 1 trade. The average volume for the last 60 days is 10,262 and the stock's 52-week low/high is $0.08/$0.49.

Sevion Therapeutics, Inc. (SVON)

Today we are reporting on Sevion Therapeutics, Inc. (SVON), here at the QualityStocks Daily Newsletter.

San Diego, California-based Sevion Therapeutics, Inc. is a biopharmaceutical company that discovers, develops, and acquires next-generation biologics. It is building and developing a portfolio of unique therapeutics, from internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company’s product candidates come from numerous key proprietary technology platforms: cell-based arrayed antibody discovery, ultralong antibody scaffolds, and Chimerasome nanocages.  Sevion Therapeutics lists on the OTC Bulletin Board.

The Company has taken advantage of the above-mentioned technologies to build a pipeline of innovative product candidates. Its antibody pipeline is undergoing development from technology, which allows for the discovery of innovative biologic therapies to previously inaccessible targets. This includes multispanning membrane proteins and ion channels that play a vital role in multiple diseases.

In addition, Sevion Therapeutics developed the first protein nanocage system enabling delivery of nucleic acids and other payloads to target cells. The Company is working together with CNA Development, LLC, an affiliate of Janssen Pharmaceuticals, Inc., to discover antibodies using Sevion’s spatially addressed library platform. The collaboration facilitated by the Johnson & Johnson Innovation center in California will include discovery of antibodies against multiple targets in a number of therapeutic areas.

Sevion Therapeutics and Janssen Pharmaceuticals will jointly conduct research on antibodies discovered by Sevion. Janssen will have an option to an exclusive license to develop, manufacture, and commercialize candidates resulting from the collaboration. Sevion Therapeutics continues to pursue partnering opportunities for its technology and drug candidates, especially in the areas of ion channel and GPCR antibody discovery.

Pertaining to SVN-001 development, the Company’s humanized cow antibody targeting the ion channel Kv1.3 for autoimmune disease was engineered to have a unique dual mode of action, which has been confirmed in T-cell inhibitory assays. The potency of SVN-001 is in the subnanomolar range in vitro.

Sevion has successfully completed an antibody discovery screening effort on internal and partnered targets. The internal discovery program includes novel oncology GPCR targets. Dr. Miguel de los Rios, PhD, VP of Research and Development, said in June, “To our knowledge we have the first antibodies against certain important GPCRs associated with several cancers.”

The Company believes it has a position in the expanding field of immuno oncology, where numerous transmembrane proteins are presently not drugged because of discovery technology limitations. Moreover, Sevion has expanded and optimized production of its arrayed antibody library. This will enhance the efficiency by which it discovers leads for difficult transmembrane targets.

Sevion Therapeutics, Inc. (SVON), closed Tuesday's trading session at $0.72, down 7.94%, on 63,838 volume with 46 trades. The average volume for the last 60 days is 55,628 and the stock's 52-week low/high is $0.51/$2.74.

GroGenesis, Inc. (GROG)

StreetAuthority Financial, ProfitableTrading, Dividend Opportunities, SECFilings.com News, Insider Wealth Alert, Investors Alley, and Flagler Financial Group reported recently on GroGenesis, Inc. (GROG), and we choose to report on the Company as well, here at the QualityStocks Daily Newsletter.

GroGenesis, Inc.’s aim is to become a leading producer of natural plant growth health technologies. It is rights holders, developers, and manufacturers of inventive plant health enhancement products branded as AgraBurst and AgraBlast. GroGenesis is working to position the Company in the quickly expanding fertilizer, surfactant, fungicide, and plant growth enhancement space as a business distinguished for safe, productive technology and proprietary solutions. GroGenesis is headquartered in Springville, Tennessee, and the Company lists on the OTC Bulletin Board.

GroGenesis’ AgraBurst is a plant growth technology blended from processed extracts of natural plant materials, which directly improves the positive effects of commercial fertilizers and available nutrients. AgraBurst™ is its flagship product. It works at the cellular level to speed up the absorption of vital nutrients, chemicals, and water through molecular penetration of the plant’s leaf.

Additionally, GroGenesis offers "AgraBlast", which is an eco-friendly, non-toxic alternative to synthetic fungicides. When used in combination (as directed), GroGenesis provides a unique solution for the control of plant pathogenic fungi and for plant remediation and stimulation of yields. AgraBlast is a broad-spectrum algaecide, fungicide, bactericide, and general sanitation product for the control and prevention of horticultural diseases and pathogens in pre-harvest, post-harvest and storage of field-grown crops.

GroGenesis is also working to become a world leading provider of eco-friendly, non-toxic, plant growth and health enhancers. In addition, it is working to enable farmers and agribusinesses to considerably boost crop yields worldwide while mitigating the effects of over-fertilization. The Company offers a technology that alleviates many of the challenges of fertilizer application through introducing a surfactant to plant foliage as a unique delivery system to hasten absorption of water and nutrients on-leaf, while simultaneously increasing root uptake.

Recently, GroGenesis advised that as part of the Company’s continuing business development process, it has resolved to refine the market segmentation and commercial roll out potential for its first two products: AgraBurst and AgraBlast. Company Management has determined (based on internal studies) to realize increased market awareness in the nascent biostimulant sector. This is a recent and growing industry classification, which shows significant promise as an agricultural interconnection of new technological advancements and commercial adoption.

GroGenesis, Inc. (GROG), closed Tuesday's trading session at $0.23, up 31.43%, on 62,682 volume with 28 trades. The average volume for the last 60 days is 105,552 and the stock's 52-week low/high is $0.11/$1.06.

Endonovo Therapeutics, Inc. (ENDV)

Epic Stock Picks, Value Penny Stocks, Hot Stock Profits, The Stock Psycho, Darth Trader, Damn Good Penny Picks, Penny Picks, Penny Stock Newsletter, and PREPUMP STOCKS reported on Endonovo Therapeutics, Inc. (ENDV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Endonovo Therapeutics, Inc. is a biotechnology company that lists on the OTC Markets Group’s OTCQB. It is developing off the-shelf, cell-free regenerative products and non-invasive, bioelectronic therapies. The design of these is to extend and enhance human life through regenerating tissues and organs that have become injured or damaged because of disease and age. Endonovo Therapeutics has its headquarters in Woodland Hills, California.

Endonovo is developing therapies for various inflammatory, autoimmune and degenerative diseases using its bio-electromagnetic platform. The Company is developing off-the-shelf regenerative products that no longer require the injection of stem cells.

Its first platform is Cell Free Therapeutics. It harnesses the biological secretions of cells to create therapies that can be immediately administered following injuries or to treat acute and chronic diseases. Cell Free Therapeutics represent a next generation of regenerative products that may be able to lessen many of the disadvantages of stem cell transplants. Endonovo Therapeutics is developing novel Cell Free Therapeutics based on the use of adult pluripotent or progenitor stem cells for the production and manufacturing of therapeutic biomolecules for use in regenerative medicine.

Endonovo’s second platform is the development of non-invasive, bioelectronics to stimulate the body's natural repair system to treat injuries and inflammatory diseases. Regarding Bioelectronics, the bioelectronics device is a portable Time-Varying Electromagnetic Field (TVEMF) system. The unit uses a sophisticated miniaturized circuit board. This board delivers the specifically designed and patented electromagnetic field to a designated area of the body through the use of antennas (coils).

This past April, Endonovo Therapeutics announced its intention to commence pre-clinical testing of its electroceutical technology to treat and reverse acute and chronic inflammatory liver pathologies. This includes the conditions that cause non-alcoholic steatohepatitis (NASH) and human cirrhotic liver disease. NASH is liver inflammation and cellular damage caused by a buildup of fat in the liver.

Endonovo Therapeutics, Inc. (ENDV), closed Tuesday's trading session at $0.56, down 18.83%, on 1,600 volume with 4 trades. The average volume for the last 60 days is 12,457 and the stock's 52-week low/high is $0.43/$3.50.

Intellect Neurosciences, Inc. (ILNS)

OtcWizard and Penny PayDay reported previously on Intellect Neurosciences, Inc. (ILNS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Intellect Neurosciences, Inc. is a biopharmaceutical company based in Englewood Cliffs, New Jersey. It engages in the discovery and development of therapeutic approaches designed to address multifactorial diseases caused by the abnormal folding of proteins (collectively known as proteinopathies). The Company is particularly focused on Alzheimer’s amyloidosis and related tauopathies. Intellect Neurosciences’ shares trade on the OTC Markets’ OTCQB.

The Company involves in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of neurodegenerative conditions, especially the above-mentioned proteinopathies. These include Alzheimer’s (AD), Parkinson’s and Huntington’s disease, Frontotemporal Dementia, and also Age Related Macular degeneration.

Intellect Neurosciences’ strategy is to develop its drug candidates to the point where they are attractive to large pharmaceutical companies. Next, its strategy is to enter into license or partnership agreements with such companies to speed-up commercialization.

Intellect Neurosciences outsources its research and development (R&D) activities. It works with academic centers of excellence and specialized contract research organizations that enables Intellect to maintain a highly efficient and cost effective structure. The Company’s internal drug discovery programs are centered on the therapeutic applications of monoclonal antibodies and antibody-drug conjugates.

Concerning Licensed Programs, the Company has OX1 – licensed to Shire plc. OX1 is an orally-administered, brain-penetrating, naturally-occurring copper-binding small molecule. It has the potential to treat various neurodegenerative diseases such as Friedreich's Ataxia and Alzheimer’s disease. Furthermore, Intellect Neurosciences has granted non-exclusive licenses related to its ANTISENILIN® patent estate to a number of worldwide pharmaceutical companies.

Intellect Neurosciences earlier announced that it has initiated a sponsored research collaboration with one of the leading Alzheimer's disease research centers in the U.S. The sponsored research collaboration is under the direction of Professor Bradley T. Hyman MD, PhD, Director, Massachusetts Alzheimer's Disease Research Center & Co-Director, Massachusetts General Hospital Memory Disorders Unit & John B. Penney Jr. Professor of Neurology, Harvard Medical School. The design of the research is to examine the detailed molecular mechanism affecting propagation of tau pathology targeted at developing a novel treatment for Alzheimer's disease and other tauopathies.

Intellect Neurosciences, Inc. (ILNS), closed Tuesday's trading session at $0.23, down 17.86%, on 584,208 volume with 210 trades. The average volume for the last 60 days is 21,535 and the stock's 52-week low/high is $0.18/$5.00.


The QualityStocks
Company Corner


On the Move Systems, Inc. (OMVS)

The QualityStocks Daily Newsletter would like to spotlight On the Move Systems, Inc. (OMVS). Today, On the Move Systems, Inc. closed trading at $0.64232, up 7.05%, on 11,403 volume with 11 trades. The stock’s average daily volume over the past 60 days is 14,413, and its 52-week low/high is $0.55/$11.04.

On the Move Systems, Inc. has signed an important letter of intent with a prominent Houston-area software design firm regarding development of its upcoming shared economy app. The online, on-demand app, when released, will revolutionize the trucking industry by connecting national and local carriers, enabling each to maximize efficiency, optimize routes and reduce costs.

On the Move Systems, Inc. (OMVS) specializes in the development of cutting-edge technology to transform and synchronize freight supply chain operations for a broad range of industries. The company is exploring new online tools to reduce costs and increase convenience in the tourism and travel industry, as well as new opportunities in trucking. OMVS works with a premier group of international providers to offer its services in two key divisions: Trucking Logistics and Inter-modal Freight.

Logistics are critical to the success of any operation. OMVS's Trucking Logistics division operates as one of the most competitive, full-service transportation logistics providers in the United States. Utilizing the company's ISTx Platform, this division helps customers strategize how to get from one point to another, as well as solves some of the toughest logistics challenges on the road today. OMVS's Trucking Logistics technology provides customers increased visibility, minimal-cost route effectiveness, and delivery assurance.

OMVS's Intermodal Freight division offers seamless cargo continuation, tracking, shipping and receiving of goods anywhere in the world. The company's customer service teams and drivers communicate through the ISTx Platform allowing for flexibility, control and monitoring of each freight shipment. OMVS continues to research and explore the most effective and resourceful tools in order to effectively serve customers with unique shipping requirements in the billion dollar trucking industry.

In his more than 20 years of experience, OMVS president and CEO Robert Wilson has cultivated vast expertise as an executive and financial consultant for companies in aviation, energy, oil and gas, IT and healthcare. In addition to his work valuing and assessing small-to-middle market companies, Wilson has also served as both an officer and director of such client companies. Wilson applies his expertise in the transportation business and investment banking to spearhead OMVS's new initiative to create a new kind of online transportation platform to an international market Disclaimer

On the Move Systems, Inc. Company Blog

On the Move Systems, Inc. News:

OMVS Inks Key LOI for Design of “Uber-for-Trucking” Shared Economy Platform

OMVS: Truckers’ Increasing Turn to Technology a Boom for Its Shared Economy Business Model

Key Trucking Industry Survey Bolsters OMVS’s Shared Economy Model

Fastfunds Financial Corp. (FFFC)

The QualityStocks Daily Newsletter would like to spotlight Fastfunds Financial Corp. (FFFC). Today, Fastfunds Financial Corp. closed trading at $0.0007, off by 12.50%, on 20,400,000 volume with 19 trades. The stock’s average daily volume over the past 60 days is 9,975,339, and its 52-week low/high is $0.0007/$0.36.

Fastfunds Financial Corp. announced today it has named Soren Holdings and Marketing (Soren) the brand and marketing specialist for the Tommy Chong Green Card. Soren will assume the role and title of Independent Brand Development Specialist. In this capacity, Soren will assist FFFC in positioning the Tommy Chong Green Card (Green Card) in the marketplace for consumer acceptance through development of product and brand definition, brand image and official product launch. In marketing, Soren will assist FFFC in the oversight and management of all approved marketing, sales and PR initiatives, all with the goal of developing nation-wide Green Card distribution and sales.

Fastfunds Financial Corp. (FFFC) operates through two wholly owned subsidiaries, Cannabis Angel, Inc. and The 420 Development Corporation, to build a portfolio of revenue-generating companies that provide ancillary services to the burgeoning cannabis industry. The company also operates majority-owned subsidiary Financiera Moderna, Inc., which offers financial services to the underserved Hispanic community. FFFC's strategy to participate in the marijuana industry is through the development of four separate business verticals for the emerging U.S. cannabis industry.

Through its 49% stake in Cannabis Merchant Financial Solutions, Inc. (CMFS), FFFC entered the Financial Service business vertical. CMFS developed the Green Card and Tommy Chong Green Card, a reloadable stored value card with a rewards feature, and the Tommy Chong Frequent Buyers Card, which functions as a gift card or rewards card. FFFC is developing a national group of master resellers, distributors and sales representatives for these card products.

As the cannabis industry continues to develop, FFFC is partaking in Plant Botany, specifically the development of methods and technologies to significantly enhance plant growth and purity. Under an operating agreement with Sanidor Systems to create Pure Grow Systems, LLC, FFFC acquired a 49% interest in the subsidiary, which is dedicated to the healthy production and processing of raw materials used for medicinal or other health related purposes.

The cannabis industry is a cash-only business, which leaves companies vulnerable to criminal activities. FFFC plans to address this issue and enter the Security Services and Equipment sector through the acquisition of an existing, operational security company. FFFC owns a 70% stake in Ohio-based Brawnstone Security, Inc., a diversified security, training and investigations company. FFFC's research shows that operating margins for cannabis-related security services could exceed current billing levels by at least 100%.

FFFC's Cannabis Angel, Inc. ("CA") subsidiary will evaluate and provide corporate development services and early seed financing for worthwhile development-stage cannabis ventures. To date, CA has made investments in companies involved in the distribution of cannabis-related products and development of a social media website. It is important to note that all of FFFCs activities in the cannabis industry are ancillary, or pick and shovel, and are evaluated to insure compliance with all state and federal Laws. Disclaimer

Fastfunds Financial Corp. Company Blog

Fastfunds Financial Corp. News:

Fastfunds Financial Corporation Announces 20 Year Veteran In Managing High Profile Celebrities And Brands Named As Brand And Marketing Specialist For Tommy Chong Green Card

Pazoo, Inc., Through Its Wholly Owned Subsidiary CannabisKing Distribution, LLC, Signs Distribution Agreement with Pure Grow Systems™, a Subsidiary of FastFunds Financial Corporation To Distribute A State Of The Art Antimicrobial Sanitation System For Grow Facilities

Fastfunds Financial Corporation Announces Major Milestone for Achieving National Distribution of Tommy Green Card

The Aristocrat Group Corp. (ASCC)

The QualityStocks Daily Newsletter would like to spotlight The Aristocrat Group Corp. (ASCC). Today, The Aristocrat Group Corp. closed trading at $1.18, even for the day. The stock’s average daily volume over the past 60 days is 2,077, and its 52-week low/high is $0.9916/$7.00.

Aristocrat Group Corp. first-ever brand-building efforts in the company’s newest vodka distribution market of Louisiana were a complete success over the weekend, with the RWB Vodka-branded car declared the overall winner of the Radical Cup Round 3 event at NOLA Motorsports Park in New Orleans. Having received 17 tasting awards over the past two years, RWB Ultra-Premium Handcrafted Vodka is among the most highly decorated American vodkas in the distilled spirits marketplace. It is the lynchpin of a growing portfolio of brands marketed and developed by the Aristocrat Group Corp. as the company works to capitalize on the rising commercial popularity of the domestic distilled spirits sector.

The Aristocrat Group Corp. (ASCC) is a brand management company specializing in the discovery and promotion of unique brands with mass market appeal. The company strategizes to capitalize on unprecedented brand-building opportunities, and is working to build a portfolio of successful brands to compete alongside industry leaders like Moet Hennessy, Louis Vuitton, Diageo PLC, and Brown-Forman Corp.

Luxuria Brands, an ASCC subsidiary, is tasked with brand management and sustainability, specifically in the beverage alcohol sector, where the company will develop and market brands using strategic, cross-cultural branding initiatives that engage businesses and consumers. Vodka boasts a significantly high market share, accounting for 25 percent of all distilled spirits sold in the United States. What this means for ASCC investors is that they have a remarkable chance to capitalize on a proven commodity and business model for distribution.

To this accord, ASCC's current portfolio of premium luxury goods brands includes top-shelf distilled spirits like RWB Vodka, an ultra-premium handcrafted spirit that has already met remarkable success, including multiple awards. The market for vodka is estimated to be at almost 60 million cases per year in the United States alone, and beverages priced at a premium level are garnering top-dollar returns for businesses and investors. Strategizing to capitalize on this powerful sector, ASCC plans to debut a second lifestyle vodka brand later this year.

ASCC's experienced and visionary management team is committed to creating a solid foundation for innovative technologies and models, ranging from mobile couponing to social engagement, that drive business forward. Building on its established presence in the lucrative beverage alcohol sector, ASCC is emerging as a trusted platform where fledgling ideas turn into commercial successes. Disclaimer

The Aristocrat Group Corp. Company Blog

The Aristocrat Group Corp. News:

ASCC: RWB Vodka Race Team Delivers the Win in New Orleans

ASCC Adds to Its Growing U.S. Distribution Network

ASCC Makes Plans to Replicate Bag-in-Box Wine’s Growth With Vodka

View Systems, Inc. (VSYM)

The QualityStocks Daily Newsletter would like to spotlight View Systems, Inc. (VSYM). Today, View Systems, Inc. closed trading at $0.0048, up 6.67%, on 12,046 volume with 4 trades. The stock’s average daily volume over the past 60 days is 520,160, and its 52-week low/high is $0.0042/$0.0269.

View Systems, Inc. (VSYM) is a leading security technology products company with “state-of-the-art” technological solutions for modern security problems. Targeting the challenging business opportunities in the opening decades of the 21st century and beyond, View Systems has solutions for law enforcement facilities such as correctional institutions as well as other government agencies, schools, courthouses, event and sports venues, the military and commercial businesses.

The senior management team is comprised of successful businessmen with decades of business and professional experience in the security industry. The approach used by View Systems utilizes the expertise of this team to provide innovative solutions to security problems with reliable “cutting edge” products in conjunction with client-oriented security consulting services.

The company’s flagship product, ViewScan, is an advanced walk-through Concealed Weapons Detection System (CWD) that greatly simplifies the process of discriminating suspicious items from harmless ones. The highly sensitive, completely passive sensor technology powering the system accurately detects the location and number of threat objects such as knives, guns and razor blades while ignoring personal artifacts like coins, keys and belt buckles. A portable version of this system has only a fifteen minute setup time using only a screwdriver and it easily fits inside a golf size case.

Experts say the security industry has been the fastest-growing sector of the global economy during the past decade. Today, it is conservatively estimated to be a $100 billion-a-year industry and growing. As the business environment continues to get more complex, especially in foreign markets, View Systems is strategically positioned to capitalize on unsurpassed opportunity. Disclaimer

View Systems, Inc. Company Blog

View Systems, Inc. News:

View Systems, Inc. Files for Patent, Begins Manufacturing of Enhanced ViewScan Product

View Systems Continues to Install Its Proprietary Scanning Systems Nationwide

View Systems, Inc. (VSYM) Announces Engagement of QualityStocks Investor Relations Services

Growblox Sciences, Inc. (GBLX)

The QualityStocks Daily Newsletter would like to spotlight Growblox Sciences, Inc. (GBLX). Today, Growblox Sciences, Inc. closed trading at $0.34, up 3.03%, on 53,606 volume with 13 trades. The stock’s average daily volume over the past 60 days is 76,770, and its 52-week low/high is $0.151/$1.51.

Growblox Sciences, Inc. (GBLX), a biopharmaceutical research and development company, is focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies for various medical conditions. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.

The company’s GrowBLOX technology suite includes the TissueBLOX, GrowBLOX, and CureBLOX equipment. Together, these components provide unparalleled control and monitoring of cannabis cultivation throughout the plant's life-cycle. These patent pending processes were designed to produce a safe and consistent cannabis product under cGMP guidelines. Utilizing a computer-regulated system that optimizes the nutrients, water, temperature, and gas levels, the GrowBLOX suite produces cannabis with more active ingredients per pound than traditional cultivation methods.

Also, based on an analysis of preclinical and clinical data from thousands of peer-reviewed studies, Growblox Sciences has identified the most effective profiles of cannabinoids and terpenes for the treatment of conditions within seven therapeutic categories. As a result of this extensive research and the analysis of the active ingredient profiles of 30,000 Cannabis strains in conjunction with a major testing lab, the company will be able to provide patients with natural cannabis strains containing the ideal ratios for treating specific diseases or symptoms.

Another significant advantage held by the company stems from an accelerated drug development program to finish in 3-5 years instead of the 15-20 years typically seen in traditional pharmaceutical development programs. Armed with an intellectual property strategy that takes full advantage of the design of the GrowBLOX technology suite and protects the valuable foundation laid, Growblox Sciences has positioned itself well for long-term success in the burgeoning cannabis space. Disclaimer

Growblox Sciences, Inc. Company Blog

Growblox Sciences, Inc. News:

GrowBLOX Receives Funding to Complete Construction of Nevada Cultivation Facility

GrowBLOX Announces Deployment of Commercial Units

Growblox Sciences, Inc. (GBLX) is “One to Watch”


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Wall Street Resources


Integrity Solution IR



By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251